Significance of HR-HPV E6/E7 mRNA detection to screen the severity of cervical cancer in relation to age

In order to determine the significance of HR-HPV (high risk HPV, HR-HPV) E6/E7 mRNA detection for screening the severity of cervical cancer in relation to age, a total of 308 patients were admitted to the Department of Gynecology at The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University between July 2017 and July 2018 and underwent LBC (Liquid Based Cytology) detection and HR-HPV E6/E7 mRNA detection. Data were then compared with the criteria laid down by the Pathology Department. The positive rate of HR-HPV E6/E7 mRNA detection was significantly higher in a CIN (cervical intraepithelial neoplasia) group than in a chronic cervicitis group. The sensitivity of LBC was higher than that for HR-HPV E6/E7 mRNA detection, while the specificity of LBC detection was higher than that of HR-HPV E6/E7 mRNA detection (p < 0.05). For women under 30 years old, the specificity of HR-HPV E6/E7 mRNA detection was lower than that of LBC detection, while the sensitivity of HR-HPV E6/E7 mRNA detection was higher than that of LBC detection. For women 30 years-of-age and above, the specificity of HR-HPV E6/E7 mRNA detection was significantly lower than that for LBC. HR-HPV E6/E7 mRNA detection has significant advantages for the screening of cervical cancer, especially in women under 30 years old.

Cervical cancer; HR-HPV; E6/E7 mRNA; LBC; Age

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020; 70: 7–30.

[2] Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. International Journal of Cancer. 2012; 131: 2929–2938.

[3] Baussano I, Elfström KM, Lazzarato F, Gillio-Tos A, De Marco L, Carozzi F, et al. Type-specific human papillomavirus biological features: validated model-based estimates. PLOS ONE. 2013; 8: e81171.

[4] Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease. 2013; 17: S1–S27.

[5] Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, et al. Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Research. 2022; 13: 200238.

[6] Zhou Y. Investigation of the clinical application value of HR-HPV DNA combined with liquid based cytology in colposcopy of cervical cancer. Contrast Media & Molecular Imaging. 2022; 2022: 5054507.

[7] Arbyn M, Simon M, de Sanjosé S, Clarke MA, Poljak M, Rezhake R, et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. The Lancet Oncology. 2022; 23: 950–960.

[8] Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, et al. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. Journal of Clinical Microbiology. 2012; 50: 2390–2396.

[9] Nikolic N, Basica B, Mandic A, Surla N, Gusman V, Medic D, et al. E6/E7 mRNA expression of the most prevalent high-risk HPV genotypes in cervical samples from Serbian women. Diagnostics. 2023; 13: 917.

[10] Bruno MT, Ferrara M, Fava V, Rapisarda A, Coco A. HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women. Virology Journal. 2018; 15: 52.

[11] Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLOS Pathogens. 2020; 16: e1008376.

[12] Li B, Guo R, Lai T, Qiao L, Fu H. The application of PAX1 methylation detection and HPV E6/E7 mRNA detection in cervical cancer screening. The Journal of Obstetrics and Gynaecology Research. 2021; 47: 2720–2728.

[13] Cesur Ö, Nicol C, Groves H, Mankouri J, Blair GE, Stonehouse NJ. The subcellular localisation of the human papillomavirus (HPV) 16 E7 protein in cervical cancer cells and its perturbation by RNA aptamers. Viruses. 2015; 7: 3443–3461.

[14] Sharma B, Lakhanpal V, Singh K, Oberoi L, Bedi PK, Devi P. Evaluation of HPV E6/E7 mRNA detection in clinically suspected cases of cervical cancer with abnormal cytology: time to upgrade the screening protocols. Journal of Laboratory Physicians. 2022; 14: 336–342.

[15] Yang YM, Wang SJ, Wang FY, Chen R, Xiao Q, Kang N, et al. Preliminary study of the use of E6/E7mRNA detection in screening and triage management of HR-HPV infection during pregnancy. Annals of Translational Medicine. 2021; 9: 1428.

[16] Bruno MT, Ferrara M, Fava V, Barrasso G, Panella MM. A prospective study of women with ASCUS or LSIL pap smears at baseline and HPV E6/E7 mRNA positive: a 3-year follow-up. Epidemiology and Infection. 2018; 146: 612–618.

[17] Derbie A, Mekonnen D, Woldeamanuel Y, Van Ostade X, Abebe T. HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review. Infectious Agents and Cancer. 2020; 15: 9.